Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects

Afshin Amini, Samar Masoumi-Moghaddam, Anahid Ehteda and David Lawson Morris

Abstract

Pseudomyxoma peritonei (PMP, ORPHA26790) is a clinical syndrome characterized by progressive dissemination of mucinous tumors and mucinous ascites in the abdomen and pelvis. PMP is a rare disease with an estimated incidence of 1–2 out of a million. Clinically, PMP usually presents with a variety of unspecific signs and symptoms, including abdominal pain and distention, ascites or even bowel obstruction. It is also diagnosed incidentally at surgical or non-surgical investigations of the abdominopelvic viscera. PMP is a neoplastic disease originating from a primary mucinous tumor of the appendix with a distinctive pattern of the peritoneal spread. Computed tomography and histopathology are the most reliable diagnostic modalities. The differential diagnosis of the disease includes secondary peritoneal carcinomatoses and some rare peritoneal conditions. Optimal elimination of mucin and the mucin-secreting tumor comprises the current standard of care for PMP offered in specialized centers as visceral resections and peritonectomy combined with intraperitoneal chemotherapy. This multidisciplinary approach has reportedly provided a median survival rate of 16.3 years, a median progression-free survival rate of 8.2 years and 10- and 15-year survival rates of 63% and 59%, respectively. Despite its indolent, bland nature as a neoplasm, PMP is a debilitating condition that severely impacts quality of life. It tends to be diagnosed at advanced stages and frequently recurs after treatment. Being ignored in research, however, PMP remains a challenging, enigmatic entity. Clinicopathological features of the PMP syndrome and its morbid complications closely correspond with the multifocal distribution of the secreted mucin collections and mucin-secreting implants. Novel strategies are thus required to facilitate macroscopic, as well as microscopic, elimination of mucin and its source as the key components of the disease. In this regard, MUC2, MUC5AC and MUC5B have been found as the secreted mucins of relevance in PMP. Development of mucin-targeted therapies could be a promising avenue for future research which is addressed in this article.

Keywords: Pseudomyxoma peritonei, PMP, Mucin, MUC2, Goblet cells, Appendix

Introduction

With an estimated incidence of 1–2 out of a million [1], pseudomyxoma peritonei (PMP, ORPHA26790)—also known as adenomucinosis or gelatinous ascites—is listed as a rare disease by the NIH Office of Rare Diseases Research (ORDR) and National Organization for Rare Disorders (NORD). As an indolent neoplasm with unspecific manifestations, PMP tends to be misdiagnosed, or discovered at advanced stages. Moreover, it is a challenging entity with debilitating, even fatal complications. Despite a multidisciplinary approach composed of an extensive surgical procedure and chemotherapy, PMP frequently recurs and increasingly jeopardizes quality of life. Being ignored in research, however, PMP remains poorly understood and enigmatic. This is despite the fact that “rare diseases are rare, but rare disease patients are numerous” [2] and those with progressive, life-threatening courses deserve to be further explored. To enhance outcomes of the conventional therapy, novel approaches based on in-depth understanding of the pathological processes and biological events in the pathogenesis of the disease are warranted. Since PMP and mucin are inextricably linked, any therapeutic intervention...
needs to properly target the mucin ectopy. In this article, the current knowledge on the crucial role of mucin in the pathogenesis of the disease is reviewed and a number of potential therapeutic strategies for mucin elimination in PMP are addressed.

Definition
PMP is characterized by dissemination of mucinous tumor implants on peritoneal surfaces and progressive accumulation of mucinous ascites throughout the peritoneal cavity resulting in the so-called "jelly belly".

Etiology
Since initial descriptions of PMP as a syndrome in association with an ovarian tumor [3] or an appendiceal mucocele [4], a pre-existing intraperitoneal mucinous neoplasm has been implicated as the primary cause of PMP. As follows, emerging evidence supports the appendiceal rather than ovarian origin of the disease.

Classification
PMP has been broadly applied to a heterogeneous group of pathological conditions with a similar clinical presentation, with the site of the primary tumor, neoplastic phenotype of the peritoneal tumor cells and classification of the disease being a matter of controversy. However, attempts have been made to better define and classify the condition based on the clinicopathological characteristics. Ronnett et al. [5] suggested a classification of multifocal peritoneal mucinous tumors into three groups. These include disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA) and a third hybrid group called peritoneal mucinous carcinomatosis with intermediate or discordant features (PMCA I/D), also known as intermediate features group (IFG). According to this clinicopathological classification, DPAM includes histologically benign peritoneal lesions associated with ruptured appendiceal mucinous adenomas as well as those with similar pathology but lacking a demonstrable appendiceal adenoma. Subsequently, Sugarbaker defined PMP as a grade I mucinous adenocarcinoma that arises from an appendiceal adenoma [6]. Later, they stipulated that the term PMP should be exclusively used to describe the clinical syndrome of mucinous ascites accompanied by a characteristic distribution of peritoneal mucinous tumors with the pathologic features of DPAM [7]. Further studies strongly supported the notion that PMP is a generally low-grade, indolent neoplasm of appendiceal origin with rare distant metastases and unlikely involvement of solid organs [1,8,9]. Since neither adenoma nor adenocarcinoma precisely represents the neoplastic nature of PMP, "mucinous neoplasm of low malignant potential" and "low-grade appendiceal mucinous neoplasm" have been proposed in the literature as the alternative terms for pathological description of the PMP tumor [10].

Pathogenesis
The pathological process starts with neoplastic transformation of the appendiceal goblet cells and subsequent formation of a primary mucinous tumor. While proliferating, tumor cells maintain their constitutive level of mucin expression. As a result, the overall secretion of mucin dramatically rises [8]. This is followed by intraluminal accumulation of mucin and eventual development of an appendiceal mucocele. A small perforation or rupture of the mucocele is the key event towards the development of PMP through which tumor cells gain access into the peritoneal cavity. Lacking cell surface adhesion molecules, the exfoliated tumor cells passively circulate with the peritoneal fluid and redistribute throughout the peritoneal cavity. As a result, tumor implants and mucin collections form at the peritoneal fluid reabsorption sites as well as within the dependent portions of the peritoneal cavity to create PMP's characteristic pattern of the peritoneal dissemination (Figure 1) [11]. Accumulating mucin increases intraabdominal pressure and compresses visceral organs. Furthermore, extensive involvement of the peritoneal surface promotes variable inflammatory and fibrotic responses in the peritoneal environment and hence the development of bowel obstruction as a fatal complication of the disease [12,13]. The detailed role of mucin in the pathogenesis of PMP will be discussed later.

Clinical presentation
The disease is usually diagnosed after the age of 40 [14], with an average age at diagnosis of 53 [15]. PMP clinically presents with a variety of unspecific and sometimes uncommon signs and symptoms. PMP's clinical manifestations can be roughly classified based on the disease progression (Table 1) [16]. In advanced disease, increased abdominal girth and complaints of abdominal pain related to intestinal obstruction are the most presenting symptom seen in 30-50% of the PMP patients as a result of disseminated mucinous tumor and ascites classically presenting at laparotomy with jelly belly. In less advanced disease, local symptoms are seen in 50-80% of PMP patients without jelly belly ascites and might correspond to the site of the primary tumor, such as appendicitis-like symptoms in 25% of cases, or the location of the peritoneal implants, including lower abdominal pain, pelvic pressure and gynecological complaints in females due to the ovarian deposits of the mucinous tumor in 20-30% of the patients [17,18]. Finally, PMP is coincidentally found in up to 20% of patients undergoing such procedures as laparotomy, laparoscopy or imaging for other medical conditions, e.g. hernia [17,27], bladder tumor [28], jelly like material in urine [29], total uterovaginal prolapse [30], recurrent rectal cancer [31], pregnancy [32] and cesarean section...
PMP cases presenting with an ulcerated skin fistula on the right flank or a subcutaneous nontender umbilical nodule have also been reported.

Diagnosis

**Imaging**

- **Ultrasound and parallel fine needle biopsy.** Ultrasound is accessible and inexpensive. However, conclusions cannot be drawn from ultrasound alone since the mucinous ascites resembles free intraperitoneal fluid. Although cytological investigation of the mucin collections seems to be a useful accompanying procedure, sampling errors, dry taps and false negative results due to low amount of mucin and/or low cellular density are considered as the disadvantages of parallel fine needle biopsy.

**Figure 1** Schematic representation of the events resulting in the development of PMP. The pathologic process starts with a neoplastic transformation of the appendiceal goblet cells and development of a primary mucinous tumor. Overproduction of mucin and obstruction of the appendiceal lumen lead to the development, and subsequent rupture, of a mucocele. Shredded tumor cells gain access to the peritoneal cavity and circulate with the peritoneal fluid. Accordingly, tumor cells redistribute and accumulate within the dependent portions of the peritoneal cavity as well as at the peritoneal fluid reabsorption sites.

**Table 1** Common presentations or incidental discovery of PMP on the basis of the disease progression

| Disease status at diagnosis | Presenting or incidentally diagnosed with |
|----------------------------|-----------------------------------------|
| Advanced disease           | Abdominal distension, ascites, obstruction [18,36] |
| Localized disease          | Abdominal pain [18]                      |
|                            | Appendicitis-like syndrome               |
|                            | Presumed cholecystitis                   |
|                            | Vague non-specific pain                  |
|                            | Lower abdominal pain/pelvic mass         |
| Less-advanced disease      | Pelvic pain/mass [18,37,38]              |
| Incidentally diagnosed     | Infertility investigation [18]            |
| disease                    | Postmenopausal bleeding [18,39]          |
|                            | Abnormal Pap test [18]                   |
|                            | Others [18]                              |
|                            | Deep vein thrombosis, rectal bleeding, anaemia |
| Non-surgical procedures    | Hemia repair, fibroids, colon cancer, tubal ligation, nephrectomy, abdominal aortic aneurysm repair |

Amini et al. Orphanet Journal of Rare Diseases 2014, 9:71
- **Computed tomography.** Computed tomography (CT) remains the most widely used imaging modality in PMP. Higher densities of mucinous ascites compared to the nonmucinous collections [40], characteristic pattern of the mucinous accumulation [41] and the extent of the disease for preoperative planning and prognostic purposes [36] can be evaluated by CT.

- **Other imaging methods.** Magnetic resonance imaging (MRI) has been described to show the location of mucocoele and its morphologic criteria identically to CT. T1- and T2-weighted MRI are more sensitive in distinguishing between mucin and fluid ascites [42-44]. Although positron emission tomography (PET) has been suggested for predicting the peritoneal dissemination [45] and preoperative evaluation of pathological grade and potential for complete cyto-resection [46], its value in PMP remains controversial [47,48].

**Circulating tumor markers**

Although relatively non-specific [14], the following tumor markers have been reported to be of value in PMP:

- **Carcinoembryonic antigen (CEA).** This tumor marker has been shown to serve as a valuable diagnostic [49] and prognostic tool [49,50] in the management of PMP.

- **Carbohydrate antigen 19.9 (CA19.9).** Practical value of CA19.9 in diagnostic [49] and prognostic [49,51-54] evaluation of PMP has been reported.

- **Carbohydrate antigen 125 (CA125) also known as MUC16.** Although suggested as a marker with diagnostic sensitivity for PMP [52], CA125 is not widely used as a tumor marker for PMP. Instead, as a gynecological tumor marker, it is recommended for exclusion of an ovarian neoplasm [16].

These tumor markers are also used as a baseline value for postoperative follow-up. Moreover, they have been reported as predictors of the completeness of cytoreductive surgery (CRS) [50,52,53,55], a significant prognostic factor for PMP.

**Histopathological analysis**

Apart from the characteristic feature of PMP as acellular to paucicellular mucin pools with variable amounts of neoplastic mucinous epithelium, immunohistochemical markers can help to identify the organ of origin. These include positive cytokeratin 20 (CK20), CEA, caudal-type homeobox protein 2 (CDX-2), and MUC2 as well as negative cytokeratin 7 (CK7) and CA125 [16]. Of particular interest is the secreted mucin MUC2 that is extensively positive in the patients. Although MUC2 has been suggested as a biological marker of PMP [56-60], its significance as a prognostic factor is a matter of controversy [61].

**Differential diagnosis**

The main entity to be considered in the differential diagnosis of PMP is peritoneal mucinous carcinomatosis arising from a primary mucinous carcinoma. Other differential diagnoses reported in the literature include endometriosis with myxoid change [62], melioidosis (a lethal infectious disease caused by *Burkholderia pseudomallei*) [63] and those with abdominal CT resemblance, e.g. extensive abdominal plexiform neurofibromatosis [64].

**Treatment**

Traditional treatment consists of repetitive surgical debulking. Due to the presence of tumor deposits after the first debulking surgery, this approach could results in short term palliation with imminent recurrence or progression, hence redo procedures and a shorter 5- to 10-year overall survival (OS) rate of approximately 50% [65-67]. A more aggressive approach by Sugarbaker [68,69] utilizes peritonectomy and visceral resections, called cytoreductive surgery (CRS), in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) that is featured by direct targeting of the microscopic disease, locoregional drug availability, minimal systemic exposure and improved drug penetration through hyperthermia. This strategy comprises the current standard of care for PMP with known benefits well-documented by us [15,53,54,70-81] and others [82-92]. Other proposed modalities include laparoscopy for less advanced disease [93,94], whole abdominopelvic radiotherapy (WAPRT) as a palliative treatment [95] and use of mucolytic [96-100], antibacterial [58,101,102] and anti-inflammatory [103] agents with potential values as complementary/adjuvant therapies.

**Prognosis**

Although PMP as a neoplastic disease runs a chronic, indolent course with late invasion and only rare metastasis outside the peritoneum, it is a morbid, recurrent condition with life-threatening complications. Biological features of the tumor [61,104] and access to the current standard of care at specialized oncology centers with a peritoneal surface malignancy program [105-110] comprise the most important prognostic determinants of PMP. Through a retrospective, multi-institutional study on 2298 patients treated at 16 specialized centers affiliated with the Peritoneal Surface Oncology Group International [15], Chua et al. reported a median survival rate of 196 months (16.3 years) and a median progression-free survival rate of 98 months (8.2 years) as well as 10- and 15-year survival rates of 63% and 59%, respectively.

**Mucin: from intestinal physiology to PMP**

**Mucin family**

Mucins are a diverse family of high molecular weight, heavily glycosylated proteins (Table 2). Also known as MUC glycoproteins, mucins are differentially expressed by specialized epithelial cells of mucosal surfaces throughout the body in a relatively organ- and cell type-specific
Mucins are categorized into membrane-associated and secreted types, with the latter being divided into gel-forming and non-gel-forming subtypes [112,113]. Membrane-associated mucins communicate information about extracellular conditions, mediate intracellular signal transduction, and contribute to morphological and behavioral characteristics of the epithelial cells [114,115].

Secreted mucins provide a physical barrier for epithelial cells lining the respiratory and gastrointestinal tracts and form the ductal surfaces of such organs as liver, breast, pancreas and kidney [116]. Moreover, they are part of a defensive system at the mucosal surfaces, including intestinal mucosa.

**Mucin in intestinal physiology**

While facilitating the transit of intestinal contents [117], secreted mucins participate in the front line of the enteric host defense generated by the alliance of the epithelial cells, immune cells and resident microbiota [118]. This interactive ecosystem is essential for the maintenance of intestinal homeostasis and the normal function and activity of digestive system [119]. The gastrointestinal epithelium and the overlying mucus layer also function as a barrier against intestinal luminal hazards [120]. Colonic mucus is composed of two layers. The outer, loose layer is the habitat of the microbial flora. The inner, dense layer is bacteria-free and firmly attached to the epithelium. This organization keeps the flora well separated from the mucosal surface. The gel-forming mucin MUC2, which is specifically secreted in the small intestine and colon, comprises the substantial component of this double-layered mucus compartment (Figure 2). MUC2 of the inner layer is uncleaved. To form the outer layer, however, MUC2 undergoes proteolytic cleavage to allow expansion of the polymeric structure [121].

**Mucin in PMP**

Under normal conditions, metabolic turnover of intestinal mucin is maintained by the constitutive expression against enzymatic degradation, and, elimination. In PMP, however, mucin is ectopically secreted and increasingly deposited in the peritoneal cavity where it is unable to degrade or drain away. Accumulating mucin causes a major part of the morbidity in PMP. The typical syndrome develops after secreted mucin forms voluminous gels over months and years. Mucin also plays a key role

| Table 2 Classification, designation and distribution of mucin family |
|-----------------|-----------------|-----------------|
| Type of mucin   | Designation     | Site of expression                                      |
| Membrane-associated | MUC1           | Almost all glandular epithelial surfaces of respiratory, gastrointestinal and female reproductive tracts, middle ear, salivary gland, mammary gland and normal pancreatic intralobular ducts |
|                 | MUC3A           | Gastrointestinal tract epithelium                        |
|                 | MUC3B           | Gastrointestinal tract epithelium                        |
|                 | MUC4            | Respiratory tract, salivary glands, stomach, colon, eye, vagina, ectocervix, uterus and prostate |
|                 | MUC11           | Gastrointestinal, respiratory, reproductive and urinary tracts, liver and thymus |
|                 | MUC12           | Colon, stomach, pancreas, prostate and uterus            |
|                 | MUC13           | Gastrointestinal and respiratory tracts, middle ear and kidney |
|                 | MUC15           | Placenta, salivary gland, thyroid gland, trachea, esophagus, kidney and testis |
|                 | MUC16           | Ocular surface, respiratory and female reproductive tracts and middle ear |
|                 | MUC17           | Gastrointestinal tract, fetal kidney and conjunctival epithelium |
|                 | MUC20           | Kidney, placenta, lung, prostate, liver, colon, esophagus, rectum and middle ear |
|                 | MUC21           | Respiratory tract, thymus, colon and testis              |
| Secreted Gel-forming | MUC2           | Goblet cells of small intestine and colon |
|                   | MUC5AC          | Tracheobronchial goblet cells, gastric epithelial cells, conjunctiva and lacrimal glands |
|                   | MUC5B           | Salivary glands, tracheobronchial and esophageal epithelium, pancreatobiliary and endocervical epithelia |
|                   | MUC6            | Gastric mucosa, duodenal Brunner’s glands, hepatobiliary tract, pancreatic centroacinar cells and duct, basal endometrial and endocervical glands |
| Non-gel-forming  | MUC19           | Salivary glands, submucosal gland of the tracheal tissue, corneal and conjunctival epithelium and lacrimal gland tissue |
|                   | MUC7            | Epithelium of the oral cavity, minor salivary gland, respiratory tract, submucosal glands of the bronchus, conjunctivae and pancreas |
|                   | MUC8            | Normal Human Nasal epithelial (NHNE) cells and middle ear epithelium |
|                   | MUC9            | Fallopian tubes (non-ciliated oviductal epithelial cells) |
Figure 2 MUC2 in colonic mucosa. A Synthesis, secretion and organization of colonic mucosa. The first stage in the biosynthesis of MUC2 is the formation of MUC2 monomer as an N-glycosylated apoprotein in the endoplasmic reticulum. Subsequently, MUC2 dimers are formed when intermolecular disulfide bonds bridge between the C-terminal cysteine knot domains. During transit through the Golgi apparatus, MUC2 dimers become heavily O-glycosylated. Complete glycosylation of the dimers occurs in Golgi where trimerization through disulfide bonds at the N-terminus forms protease-resistant trimers. The fully glycosylated and processed MUC2 is densely packed and stored in secretory granules/vesicles and released through constitutive or stimulated secretory mechanisms. Once released, MUC2 is organized into the firmly adherent inner layer. At a certain distance from the epithelium, this layer is converted into the loose outer layer through proteolytic cleavage and expansion. Mucus also contains immunoglobulins and other proteins.

B MUC2 structure. The protein core consists of five different regions. Segment (a) and (b) are two central repetitive regions rich in potential O-glycosylation sites, to which branched carbohydrate chains of 4–12 sugars are O-glycosidically linked to form a closely packed sheath around the central protein core. Segment (a), also known as VNTR domain, is a large domain that contains 50–100 “variable number of tandem repeats (VNTRs)” of 23 amino acids, in particular, threonine. Segment (b), also called DTS domain, is a 347 amino acid domain, containing irregular repeats rich in proline, threonine and serine (PTS). These two segments are linked together by segment (c) which is a 148 amino acid, cysteine containing region. Segments (d) and (e) are extensive peptide chains rich in cysteine located at the C and N terminal ends, respectively, containing D domains with sequence homology to von Willebrand factor. These regions are the presumed sites for end to end polymerization of mucin subunits.
in the biology of the PMP tumor. Most of the tumor cells are surrounded by a mucin coat that allows them to freely move, disseminate and “redistribute” within the peritoneal cavity to create the distinctive feature of PMP. This coating also seems to act as a protective shield against immune recognition and chemotherapy. MUC2, MUC5AC and MUC5B are the gel-forming mucins reportedly found in the PMP secretions. The intestinal mucin MUC2 is known as the PMP-specific mucin. According to O’Connell et al. [8,56], primary ovarian mucinous tumors essentially express MUC5AC whereas solitary appendiceal mucinous tumors and different categories of PMP express MUC2 along with MUC5AC. This finding also supports the notion that PMP is a neoplasm of appendiceal origin. In their studies, O’Connell et al. also showed that MUC2 is behind the high degree of gelation formed in PMP. Since MUC2 is more extensively glycosylated, it is more voluminous than MUC5AC on an equimolar basis, hence formation of abundant mucinous collections where the average mucin:cell ratio is higher than 10:1. Taken together, the investigators concluded that PMP is a disease of the MUC2-secreting goblet cells and that MUC2 could serve as a molecular marker for PMP [8,56]. Since the expression level of MUC2 in PMP is seemingly independent of the degree of the malignant transformation, prognostic significance of MUC2 is controversial [61].

In two case studies, Mall et al. reported the presence of MUC5B, in addition to MUC2 and MUC5AC, in the PMP material [122,123]. Based on the investigations by Sheehan et al. implicating a low-charge glycoform of MUC5B in the production of a tenacious respiratory mucus plug [124,125], Mall et al. speculated that it may be MUC5B that is responsible for the semisolid material found in some PMP patients. Given the high protein content of the PMP secretions, they also raised the possibility that interactions between mucin and non-mucin proteins could contribute to the viscous nature of the PMP exudates [122,123]. Table 3 summarizes a number of studies in which disease-specific expression pattern of MUC2 and other mucins in PMP has been explored.

Mucin elimination in the management of PMP

Mucin comprises the cornerstone of the PMP pathogenesis. However, optimal removal of mucin and mucinous implants via conventional therapies remains challenging, with the residual disease accounting for the recurrence of the condition. In order to enhance the current standard of care, novel strategies are required to more effectively eliminate mucin and its source. As such, some efforts have been made to disrupt PMP production of MUC2. In this regard, targeting biological mechanisms regulating the mucin synthesis at transcriptional and post-transcriptional levels could be of potential value. Since MAPK pathway has been implicated in the pathological induction of MUC2 by Pseudomonas aeruginosa infection [131] and mucoepidermoid carcinogenesis [132], targeted inhibition of MAPK might be of therapeutic benefit in PMP. On the basis of the cross-talk between MAPK and other inflammation-associated signaling pathways [133], multi-targeted agents may be more effective in PMP where the disease develops within an inflammatory milieu [134].

In addition, PMP inflammatory microenvironment with a unique profile of cytokines [13] contributes to the mucin overproduction. Cytokines reportedly upregulate the expression of MUC2 and enhance the mucin secretion [135-137]. Glucocorticoids, on the other hand, have been shown to downregulate MUC2 via direct inhibition of glucocorticoid response elements (GREs) and indirect transrepression of inflammation-associated transcription factors [138,139]. Choudry et al. recently demonstrated dexamethasone- and celecoxib-induced inhibition of the mucin production in a mucin-secreting cancer cell line with goblet cell phenotype as well as in a murine model of PMP [103]. Methylation of the MUC2 promoter has also been suggested as a potential tool for manipulating the expression of MUC2. Okudaira et al. showed that colorectal cancer (CRC) cell lines of mucinous type exhibit low-level methylation at the MUC2 promoter as compared to non-mucinous cell lines. They concluded that low methylation status of the MUC2 gene plays a predominant role in the high level MUC2 expression in mucinous CRC [140]. Through inhibiting the MUC2 promoter methylation, the Sp-family of transcription factors augments MUC2 expression. Thus, mithramycin, a Sp1 binding site inhibitor, effectively blocks the MUC2 expression in colorectal cancer [132,141].

Breakdown of mucin as well as enhancement of cytoreduction through locoregional therapies outlines our intended approach to this challenge. In this regard, we aim to develop a novel treatment for facilitated, enhanced removal of the mucin-tumor burden at both macroscopic and microscopic levels. For this purpose, a panel of mucin-secreting cancer cells of gastrointestinal and peritoneal origin and animal models of PMP [142] and peritoneal carcinomatosis [143] are employed in our preclinical investigations. Among a number of mucolytic agents studied [99,100], bromelain and N-acetyl cysteine (NAC), two generally-safe mucolytics of plant sources [144,145], have shown promise. Our preliminary results indicate bromelain- [146-148] and NAC-induced inhibition of the growth and proliferation of the mucin-producing cancer cells in vitro, with the cytotoxicity being augmented when the two are used in combination (unpublished data). We have also observed the ability of these mucolytics in dissolving both the mucin samples from PMP patients ex vivo and the mucin implants in a
A xenograft model of PMP in vivo with no treatment-related toxicity in rats [149]. We are currently performing final preclinical testing of our mucolytic compound before proceeding to the clinical phase.

**Conclusion**

Despite its morbid, debilitating nature with severe impact on quality of life, PMP remains orphan and enigmatic. Essential for physiological function of the gastrointestinal tract, mucin is the major contributor to the pathophysiology of PMP. Peritoneal implantation of the tumor cells originating from an appendiceal mucinous tumor results in the progressive accumulation of ectopic mucin. Given the clinicopathological profile of the disease compatible with an indolent, generally low grade malignancy, multifocal collections of voluminous mucin and the ensuing complications are the main determinants of the disease prognosis. As the predominant, gel-forming mucin secreted in PMP, MUC2 is responsible for the high degree of gelation and the characteristic feature of the clinical syndrome. Despite the current standard of care as extensive surgical resection combined with chemotherapy, PMP frequently recurs; with treatment options being limited at recurrence. On this basis, in-depth investigations are warranted to illuminate unknown aspects of the disease and to seek novel therapeutic approaches for an enhanced treatment. Owing to the substantial role of mucin in the pathogenesis of PMP, development of strategies for targeting mucin and its biology seems to be of particular significance that needs to be further explored in future studies.

### Table 3 Some studies exploring the expression of MUC2 against other mucins in PMP (2002–2012)

| Study                  | Year | Number of PMP cases | Percentage of cases exhibiting the expression of mucins |
|------------------------|------|---------------------|-------------------------------------------------------|
| O’Connell et al. [8]   | 2002 | 100                 | 98% MUC5AC 95%                                        |
| O’Connell et al. [56]  | 2002 | 25                  | 96% MUC5AC 92%                                        |
| Mohamed et al. [126]   | 2004 | 33                  | 97% MUC1 57.5%                                        |
| Kinkor et al. [127]**  | 2005 | 3                   | ? -                                                   |
| Nonaka et al. [128]    | 2006 | 42                  | 100% MUC5AC 100%                                     |
| Mall et al. [122]      | 2007 | 1                   | 100% MUC5AC 100%                                     |
| Ferreira et al. [129]  | 2008 | 7                   | 100% MUC1 28.6% MUC5AC 100% MUCB 100%               |
| Semino-Mora et al. [58]** | 2008 | 16                  | N/A‡ MUC5AC 87.5%                                    |
| Baratti et al. [61]*** | 2009 | 85                  | 100% MUC5AC 0% MUC4 100%                             |
| Flatmark et al. [59]   | 2010 | 5                   | 100% MUC1 0% MUC5AC 40% MUC4 100%                   |
| Guo et al. [60]        | 2011 | 35                  | 94.3% MUC1 0%                                        |
| Mall et al. [123]      | 2011 | 1                   | 100% MUC1 0% MUC4 100% MUC5AC 100% MUCB 100% MUC6 0% |
| Chang et al. [130]**** | 2012 | 4                   | 64%† MUC5AC 43%‡‡                                    |

*Full-text article, in Czech, not accessible. Results of IHC study not available.

**This study reports the expression of MUC2 and MUC5A as the volumetric density of apomucin (Vv/10^4 μm) in such compartments of DPAM and PMCA tissues as epithelium, lymphoid aggregates, stroma vessels and free mucin, respectively, as follows:

‡MUC2: in DPAM: 264 ± 60, 47 ± 16, 31 ± 14 and 261 ± 51; in PMCA: 356 ± 90, 170 ± 26, 117 ± 25 and 1043 ± 282.

‡‡MUC5AC: in DPAM: 90 ± 13, 345 ± 20, 65 ± 17, 37 ± 6; in PMCA: 56 ± 12, 246 ± 17, 50 ± 15 and 48 ± 9.

***The percentages shown for this study are numerical estimations of data originally presented in a column graph.

****In this study, among a total of 14 patients with mucinous adenocarcinoma, 4 cases have reportedly exhibited PMP syndrome. Results of the expression of MUC2 and MUC5AC, however, are reported in total, with no data individually available regarding the PMP cases.

†, ††| Data shown is the percentage of MUC2/MUC5AC expression in all patients with mucinous adenocarcinoma, including PMP ones.

†, ††| Data shown is the percentage of MUC2/MUC5AC expression in all patients with mucinous adenocarcinoma, including PMP ones.
Acknowledgments

The authors declare that they have no competing interests.

Authors' contributions

AA designed and performed the systematic literature search supervised by DLM. AA drafted and edited the manuscript. SMM and AE reviewed the initial draft. All authors read and approved the final manuscript.

Received: 28 February 2014 Accepted: 22 April 2014

Published: 5 May 2014

References

[References are not explicitly listed in the image, but they are likely to be included in the full text of the document.]
41. Sulkin TV, O'Neill H, Amin A, Moran B. CT in pseudozystoma peritonei: a review of 17 cases. Clin Radiol 2002, 57:608–613.
42. Buy JN, Malbec L, Ghosssain MA, Guinet C, Ecoffier J. Magnetic resonance imaging of pseudozystoma peritonei. Eur J Radiol 1989, 9:115–118.
43. Matsuoka Y, Masutomo T, Suzuki K, Terada K, Ushimi T, Yokoyama Y, Abe K, Kamata N, Yasuno M, Hishima T. Pseudozystoma peritonei: retrospective evaluation. Eur Radiol 1999, 9:457–459.
44. Fairrise A, Babary C, Derelle A, Tissier S, Granger P, Marchal F, Laurent V, Regent D. [Mucocoles of the appendix and pseudozystoma peritonei]. J Radiol 2008, 89:751–762.
45. Yang QM, Bando E, Kawamura T, Tsukiyama G, Nemoto M, Yonemura Y, Matsuoka Y, Masumoto T, Suzuki K, Terada K, Ushimi T, Yokoyama Y, Abe K, Amini.
60. Guo AT, Song X, Wei LX, Zhao P: Histological origin of pseudozystoma peritonei in Chinese women: clinicopathology and immunohistochemistry. World J Gastroenterol 2011, 17:3531–3537.
61. Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterra B, Deraco M: Pseudozystoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg 2009, 249:243–249.
62. Clement PB, Giana CO, Young RH. Scully RE. Endometriosis with myxoid change. A case simulating pseudozystoma peritonei. Ann J Surg Pathol 1994, 18:849–853.
63. Sugit Subramaniam RV, Karthikeyan VS, Sista SC, Ali MS, Sista S, Ram D, Sudhagar R: Meliodosis presenting as pseudozystoma peritonei: yet another pretense of the great mimicer: an unreported entity. Surg Infect (Larchmt) 2013, 14:415–417.
64. Misch DR, Gray RR, Grossman H: Abdominal plexiform neurofibromatosis simulating pseudozystoma peritonei on computed tomography. J Comput Assist Tomogr 1989, 13:709–711.
65. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, Naessens JM, O'Brien PC, van Heerden JA: Pseudozystoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg 1994, 219:112–119.
66. Miner T, Sia J, Jacques DP, Klimstra DS, Brennan MF, Cott DG. Long-term survival following treatment of pseudozystoma peritonei: an analysis of surgical therapy. Ann Surg 2005, 241:300–308.
67. Javineen P, Javineen HJ, Lepisto A: Survival of patients with pseudozystoma peritonei treated by serial debulking. Colorectal Dis 2010, 12:868–872.
68. Sugarbaker PH: Cytoreductive surgery and intraperitoneal chemotherapy with peritoneal spread of cystadenocarcinoma. Ann J Surg Suppl = Acta chirugica Supplement 1991, 56:75–82.
69. Sugarbaker PH: Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudozystoma peritonei syndrome. Eur J Surg Oncol 2001, 27:239–243.
70. Hadi R, Saunders V, Uttika O, Clingan P, Kam P, Links M, Morris DL: Review of patients with peritoneal malignancy treated with peritoneectomy and heated intraperitoneal chemotherapy. ANZ J Surg 2006, 76:156–161.
71. Yan TD, Links M, Xu ZY, Kam PC, Glenn D, Morris DL: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudozystoma peritonei from appendiceal mucinous neoplasms. Br J Surg 2006, 93:1270–1276.
72. Chua TC, Yan TD, Smigielski ME, Zhu KJ, Ng KM, Zhao J, Morris DL: Long-term survival in patients with pseudozystoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol 2009, 16:1903–1911.
73. Chua TC, Laiw W, Morris DL: The St George Hospital peritoneal surface malignancy program–where are we now? ANZ J Surg 2009, 79:416–418.
74. Saxena A, Yan TD, Chua TC, Morris DL: Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudozystoma peritonei. Ann Surg Oncol 2010, 17:1291–1301.
75. Chua TC, Baker B, Yan TD, Zhao J, Morris DL: Palliative effects of an incomplete cytoreduction combined with perioperative intraperitoneal chemotherapy. Ann J Clin Oncol 2010, 33:568–571.
76. Chua TC, Al-Zahrani A, Saxena A, Laiw W, Zhao J, Morris DL: Secondary cytoreduction and perioperative intraperitoneal chemotherapy after initial debulking of pseudozystoma peritonei: a study of timing and the impact of malignant dedifferentiation. J Am Coll Surg 2010, 211:526–535.
77. Chua TC, Martin S, Saxena A, Laiw W, Yan TD, Zhao J, Leit K, Morris DL: Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program. Ann Surg Oncol 2010, 17:323–329.
78. Chua TC, Al-Zahrani A, Saxena A, Glenn D, Laiw W, Zhao J, Morris DL: Determining the association between preoperative computed tomography findings and postoperative outcomes after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudozystoma peritonei. Ann Surg Oncol 2011, 18:1582–1589.
79. Chua TC, Laiw W, Zhao J, Morris DL: Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudozystoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate. Ann Surg 2011, 253:769–773.
Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum 2007, 50:37–42.

Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA: Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999, 6:277–731.

Correspondence on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 2008, 98:277–282.

Andreasson H, Graf W, Nygren P, Glimelius B, Mahteme H: Proposed classification of pseudomyxoma peritonei occurring 35 years after appendectomy: a case report and review of the literature. World J Surg Oncol 2004, 2:19.

Thompson MA, Ashton RC, Knize HC: Mucinous appendiceal adenocarcinoma presenting 5 years after appendectomy. Ann Int Med 2004, 140:693.

Vandecasteele K: Whole abdominopelvic radiotherapy in the palliative treatment of appendiceal malignancy. Strahlenther Onkol: Organ der Deutsch Rontgen Gesellsch 1993, 223:1366–1372.

Kuijpers AM, Mirck B, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, van Aalten SM, Amini K, Kusamura S, Takizawa T: Pseudomyxoma peritonei occurring 5 years after appendectomy. Ann Intern Med 2007, 146:1109–1112.

Spilioti J, Efstathiou E, Halika E, Vassilaidou A, Datsis A, Sugarbaker P: The influence of tumor cell entrainment phenomenon on the natural history of Pseudomyxoma peritonei syndrome. Hepatogastroenterology 2012, 59:705–708.

Gurr JR Jr: Mucin genes and the proteins they encode: structure, diversity, and regulation. Am J Respir Cell Mol Biol 1992, 5575–564.

Rose MC, Voynov JA: Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006, 86:245–287.

Williams OW, Shariqanawen A, Kim V, Dickey BF, Evans CM: Airway mucus: production from secretion to clearance. Am J Respir Cell Mol Biol 2006, 34:527–536.

Hollingsworth MA, Swanson BJ: Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004, 4:450–465.

Rachagni S, Torres MP, Moniaux N, Batra SK: Current status of mucins in the diagnosis and therapy of cancer. Biofactors 2009, 35:509–527.

Kufe DW: Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009, 9:874–885.

Cone RA: Barrier properties of mucin. Adv Drug Deliv Rev 2009, 61:75–85.

Liev-Le Moal V, Servin AL: The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucus, antimicrobial peptides, and microbiota. Clin Microbial Rev 2006, 19:315–337.

McCracken VJ, Lorenz RG: The gastrointestinal ecosystem: a precarious alliance among epithelium, immunity and microbiota. Cell Microbiol 2001, 3:11–11.

Dharmar A, Sinavasta V, Kisooson-Singh V, Chadee K: Role of intestinal mucus in innate host defense mechanisms against pathogens. J Innate Immun 2009, 1:123–135.

Johansson ME, Larsson JM, Hansson GC: The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci U S A 2011, 108(Suppl 3):5469–5466.

Mallick AS, Chirwa N, Governador D, Lott Z, Tyler M, Rodrigues J, Kahn D, Goldberg P: MUC2, MUC5AC and MUC5B in the mucosa of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study. Pathol Int 2007, 57:537–547.

Mallick AS, Lott Z, Tyler M, Goldberg P, Rodrigues J, Kahn D, Chirwa N, Governador D: Immunohistochemical and biochemical characterization of pseudomyxoma peritonei. Rev Hosp Clin Fac Med Sao Paulo 1995, 48:301–304.
mucin in pseudomyxoma peritonei: a case study. Case Rep Gastroenterol 2011, 5:5–16.

124. Sheehan JK, Richardson PS, Fung DC, Howard M, Thornton DJ: Analysis of respiratory mucous glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol 1995, 13:746–756.

125. Sheehan JK, Howard M, Richardson PS, Longwill T, Thornton DJ: Physical characterization of a low-charge glycoform of the MUC5B mucin comprising the gel-phase of an asthmatic respiratory mucous plug. Biochem J 1999, 338(Pt 1):507–513.

126. Mohamed F, Getfher S, Haliba M, Brun EA, Sugarbaker PH: Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process. J Surg Oncol 2004, 86:10–15.

127. Kinser Z, Michal M: Syndrome of pseudomyxoma peritonei—description of three cases and survey of the problem. Ceska Gynekol 2005, 70:67–72.

128. Nonaka D, Kusamura S, Baratti D, Casali P, Younan R, Deraco M: Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinous type: immunohistochecmical evidence that they are secondary tumors. Int J Gynecol Cancer 2008, 18:59–65.

129. Chang MS, Byeon SJ, Yoon SO, Kim BH, Lee HS, Kang GH, Kim WH, Park KJ: Leptin, MUC2 and mTOR in appendical mucinous neoplasms. Pathobiology 2012, 79:45–53.

130. Li JD, Feng W, Gallup M, Kim JH, Younan R, Deraco M: Mucin expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. Histopathology 2006, 49:381–387.

131. Enss ML, Cornberg M, Wagner, S, Gebert A, Henrichs M, Eisenblatter RW, Hedrich HJ: Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. Inflamm Res 2000, 49:162–169.

132. Kim YD, Kwon EJ, Kwon TK, Baek SH, Song SY, Suh JS: Regulation of IL-1beta-mediated MUC2 gene in NCI-H292 human airway epithelial cells. Biochem Biophys Res Commun 2000, 274:112–116.

133. Iwashita J, Sato Y, Sugaya H, Takahashi N, Sasaki H, Abe T: mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase cascade and Sp1. J Biol Chem 2002, 277:3258–3267.

134. Okudaira K, Kakar S, Cun L, Choi E, Decamillis R, Miura S, Sleisenger MH, Kownatzki R, Hedrich HJ: Dexamethasone suppresses mucus production and MUC-2 and MUC-5 AC gene expression in NCI-H292 cells. Am J Physiol 1996, 271:L484–L488.

135. Enss ML, Cornberg M, Wagner, S, Gebert A, Henrichs M, Eisenblatter RW, Hedrich HJ: Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. Inflamm Res 2000, 49:162–169.

136. Kim YD, Kwon EJ, Kwon TK, Baek SH, Song SY, Suh JS: Regulation of IL-1beta-mediated MUC2 gene in NCI-H292 human airway epithelial cells. Biochem Biophys Res Commun 2000, 274:112–116.

137. Iwashita J, Sato Y, Sugaya H, Takahashi N, Sasaki H, Abe T: mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a mitogen-activated protein kinase pathway in human colon cancer cells. Immunol Cell Biol 2003, 81:275–282.

138. Kai H, Yoshitake K, Hisatsune A, Kid0 T, Ishiiwa Y, Takahama K, Miyata T: Dexamethasone suppresses mucus production and MUC-2 and MUC-5 AC gene expression by NCI-H292 cells. Am J Physiol 1996, 271:L484–L488.

139. Schoneveld DI, Gaemers IC, Lamers WH: Mechanisms of glucocorticoid signalling. Biochim Biophys Acta 2004, 1680:114–128.

140. Okudaira K, Kakar S, Cun L, Choi E, Wu Decamilis R, Miura S, Sleisenger MH, Kim YS, Deng G: MUC2 gene promoter methylation in mucinous and non-mucinous colorectal cancer tissues. Int J Oncol 2010, 36:765–775.

141. Amini A, Ehteda A, Akhter J, Pillai K, Morris DL: A new peritoneal carcinomatosis model in cyclcoporine immunosuppressed rats. Anticancer Res 2008, 28:105–108.

142. Bromelain. Monograph. Altern Med Rev 2010, 15:361–368.

143. N-acetylcysteine. Altern Med Rev 2000, 5:467–471.

144. Armin I, Ehteda A, Masoomi Moghadam S, Akhter J, Pillai K, Morris DL: Cytotoxic effects of bromelain in human gastrointestinal carcinoma cell lines (MKN45, KATO-III, HT29-5F12, and HT29-5M21). Oncs Targets Ther 2013, 9:403–409.

145. Pillai K, Akhter J, Chua TC, Morris DL: Anticancer property of bromelain with therapeutic potential in malignant peritoneal mesothelioma. Cancer Invest 2013, 31:241–250.

146. Pillai K, Ehteda A, Akhter J, Chua TC, Morris DL: Anticancer effect of bromelain with and without cisplatin or 5-FU on malignant peritoneal mesothelioma cells. Anti-cancer drugs 2014, 25:150–160.

147. Pillai K, Akhter J, Chua TC, Morris DL: A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei. Int J Cancer 2014, 134:478–486.